Tornier N.V. Sets New 52-Week High at $22.33 (TRNX)
Tornier N.V. (NASDAQ:TRNX) reached a new 52-week high during mid-day trading on Wednesday , American Banking News.com reports. The stock traded as high as $22.33 and last traded at $22.16, with a volume of 428,378 shares traded. The stock had previously closed at $21.70.
TRNX has been the subject of a number of recent research reports. Analysts at Summer Street upgraded shares of Tornier N.V. from a “sell” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $18.00 price target on the stock, up previously from $16.00. Analysts at Wells Fargo & Co. upgraded shares of Tornier N.V. from a “market perform” rating to an “outperform” rating in a research note on Thursday, March 20th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.86.
The stock’s 50-day moving average is $19.31 and its 200-day moving average is $18.98. The company’s market cap is $1.077 billion.
Tornier N.V. (NASDAQ:TRNX) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $89.00 million for the quarter, compared to the consensus estimate of $80.41 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. Analysts expect that Tornier N.V. will post $-0.45 EPS for the current fiscal year.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.